{"id":"ws016","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, WS016 reduces glucose reabsorption in the kidneys, leading to decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.","oneSentence":"WS016 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:11.512Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07251309","phase":"PHASE3","title":"A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia","status":"RECRUITING","sponsor":"Waterstone Pharmaceutical (Wuhan) Co., LTD.","startDate":"2024-12-23","conditions":"Hyperkalemia","enrollment":420},{"nctId":"NCT06281470","phase":"PHASE1","title":"The Safety and Tolerability of WS016 in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Waterstone Pharmaceutical (Wuhan) Co., LTD.","startDate":"2023-02-13","conditions":"Hyperkalemia","enrollment":66},{"nctId":"NCT06277128","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.","status":"UNKNOWN","sponsor":"Waterstone Pharmaceutical (Wuhan) Co., LTD.","startDate":"2023-09-11","conditions":"Hyperkalemia","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"WS016","genericName":"WS016","companyName":"Waterstone Pharmaceutical (Wuhan) Co., LTD.","companyId":"waterstone-pharmaceutical-wuhan-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"WS016 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}